Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S372-S377, March 2004

Experience with cyclosporine in endogenous uveitis posterior

  • D.A Hesselink

      Affiliations

    • Internal Medicine, Renal Transplant Unit (D.A.H.), Erasmus Medical Center, Rotterdam, The Netherlands
    • Corresponding Author InformationAddress reprint requests to D.A. Hesselink, Room Ee 563a, Department of Internal Medicine, Renal Transplant Unit, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.
    • ,
  • G.S Baarsma

      Affiliations

    • Department of Ophthalmology (G.S.B.), Eye Hospital Rotterdam, Rotterdam, The Netherlands
    • ,
  • R.W.A.M Kuijpers

      Affiliations

    • Ophthalmology (R.W.A.M.K.), Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • P.M van Hagen

      Affiliations

    • Clinical Immunology (P.M.V.H.), Erasmus Medical Center, Rotterdam, The Netherlands

Abstract 

Treatment with cyclosporine (CsA) has considerably improved the visual prognosis of patients suffering from endogenous posterior uveitis (EPU). However, the therapeutic benefits of CsA are partially outweighed by its many side effects, most notably nephrotoxicity and hypertension. Low-dose CsA regimens have reduced toxicity but have not been able to completely eliminate this problem. New therapeutic approaches, such as anti-tumor necrosis factor α treatment or immunosuppression with drugs including tacrolimus, sirolimus, and interleukin-2 receptor antibodies, are currently under evaluation. Hopefully such strategies will further reduce the morbidity of EPU and minimize the adverse effects associated with conventional therapies.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0041-1345(04)00004-1

doi:10.1016/j.transproceed.2004.01.003

Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S372-S377, March 2004

Article Tools